Avista Public Acquisition Corp. II
AHPAW
NASDAQ Capital Market0.69
USD
-0.06
- -
CIK
0001846253
Return %
Stock
S&P500
1Y
50.78
26.53
3Y
45.41
76.60
5Y
45.41
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 65 East 55th Street New York City NY United States of America 10022
- IPO Date
- Sep 30, 2021
- CIK
- 0001846253
- Similar Companies
- Business
- Avista Public Acquisition Corp. II (NASDAQ:AHPAW) operates as a special purpose acquisition company (SPAC) that completed its initial public offering in August 2021, raising $230 million through 23 million units priced at $10 each; the units comprise Class A ordinary shares and one-third of a redeemable warrant exercisable at $11.50 per share, with warrants trading separately under AHPAW following unit separation in September 2021. Incorporated as a Cayman Islands exempted company in 2021 and headquartered in New York, the SPAC focuses on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations targeting companies in the healthcare industry, with additional emphasis on technology and sustainability sectors. It maintains cash in trust for deployment in acquisitions valued between $500 million and $1.5 billion, leveraging sponsor Avista Capital Partners' expertise in healthcare private equity without conducting independent operations or generating revenues prior to a combination. In November 2022, Avista Public Acquisition Corp. II completed a business combination with OmniAb, Inc., a provider of antibody discovery platforms, following shareholder approval on October 24, 2022, and domestication from Cayman Islands to Delaware; the merger, originally announced in March 2022 as a spin-off from Ligand Pharmaceuticals valued at approximately $884 million, resulted in OmniAb listing under OABI with AHPAW warrants continuing as OABIW exercisable into OmniAb shares until January 2027. Post-merger, the SPAC structure transitioned fully to OmniAb, with approximately $95 million in cash at closing after redemptions and transaction expenses, supported by a $15 million PIPE investment and $100 million redemption backstop guaranteed by Avista. As of late 2025, AHPAW warrants remain quoted on NASDAQ exchanges, reflecting ongoing trading activity tied to the combined entity's performance, though the original SPAC has no independent products or services beyond its merger vehicle role.